0.05％丙酸克罗倍他索(Clobetasol Propionate)双盲试验治疗白癜风

近年来有局部应用皮质类固醇治疗白癜风取得色素再生的报告。丙酸克罗倍他索(CP)之血管收缩能力比17-戊酸倍他米松(betamethasone17-Valerate)强5倍,因此作者选择25名双侧病损大小、病期相称的白癜风患者,早晚外用一次0.05％CP霜及单纯霜基质作为对照,进行双盲试验治疗。每月评价疗效一次,共4个月。结果,除2名患者未完成疗程外,其余23名中12名(52％)用CP霜之白斑有色素再生(10名恢复15～25％,2名恢     

派瑞松霜治疗异位性皮炎疗效观察

采用自身双侧对比法治疗 37例异位性皮炎。结果派瑞松霜痊愈 11例 (29.7％ ),显效 21例 (56.8％ ),好转 2例 (5.4％ ),无效 3例 (8.1％ ),对照组皮康霜痊愈 7例 (18.9％ ),显效 9例 (24.3％ ),好转 8例 (21.6％ ),无效 13例 (35.1％ )。派瑞松霜的疗效明显优于皮康霜 (χ 2=15.18,P< 0.01)。     

局部抗菌剂的接触过敏

对101例可疑由局部抗菌剂引起接触皮炎的患者,用市售药物作斑贴试验,其阳性例数/受试例数如下:0.2％硝基呋喃唑啉油膏为56/73,0.35％硫酸新霉素油膏为28/70,0.1％庆大霉素霜为13/66,1％新霉素 B 霜为13/68,3％四环素油膏为13/69,0.05％短杆菌素霜为13/65,青霉素油膏(每克含青霉素钾盐5000u)为12/46,三磺霜(含磺胺唑啉3.42％、乙酰磺胺2.86％、N-苯甲磺胺嘧啶3.7％)为9/66,2％红汞为9/66,0.1％吖啶黄为4/68,1％     

卡介苗素与维A酸霜治疗扁平疣临床观察

目的：观察用卡介苗素与维A酸霜联合治疗扁平疣的疗效。方法：治疗组用卡介苗素注射液肌肉注射，每次2mL(1mg)，每周3次，8周为1疗程，并每晚外涂维A酸霜1次。对照组用维A酸霜每晚外涂1次，8周为1疗程。结果：在治疗组中，痊愈的48例(60％)，显效22例(27．5％)，总有效率87.5％；在对照组中，痊愈的16例(22．9％)，显效21例(30％)，总有效率52．9％。两组比较有显著性差异(P＜0．01)。结论：卡介苗素与维A酸霜联合治疗扁平疣的疗效显著并优于对照组。     

派瑞松霜与盐酸特比萘芬乳膏治疗面部脂溢性皮炎的疗效对比

目的 比较派瑞松霜与盐酸特比萘芬乳膏(兰美抒霜)外用治疗面部脂溢性皮炎的疗效。方法 将面部脂溢性皮炎患者随机分为2组：治疗组45例，外用派瑞松霜，对照组42例，外用兰美抒霜，两组均为每日1次，疗程2周。结果 治疗组的痊愈率为68．89％，总有效率为95．56％；对照组的痊愈率为47．62％，总有效率为76．19％。经x^2检验，两组间差异有显著性，派瑞松霜的疗效优于兰美抒霜，未发现派瑞松霜有不良反应。结论 派瑞松霜治疗面部脂溢性皮炎更有效，更安全。     

派瑞松霜治疗皮炎湿疹的疗效观察

目的观察派瑞松霜治疗皮炎湿疹的疗效、耐受性及不良反应。方法60例患者来自门诊和住院病人,男55例,女5例。年龄14～87岁,平均71.1±15.1岁;病程2天～20年,平均9.5±25.1月。每日2次外用派瑞松霜涂于患处,每周随访1次,共3周。结果治愈33例(55.0％),显效16例(26.7％),好转4例(6.6％),无效7例(11.7％)。总有效率为81.7％,未发现不良反应。结论派瑞松霜是治疗皮炎湿疹类皮肤病的安全、有效药物。     

多中心随机双盲观察Locoid脂霜每日两次与Locoid脂霜和基质每日各一次外用的疗效比较

异位性皮炎为常见病,常外用润滑剂、口服抗组胺药和外用皮质类固醇。Locoid脂霜是外用皮质类固醇制剂,含0.1％17-丁酸氢化可的松的水包油型乳剂,赋形剂为70％的脂肪物质和30％的水。 该文进行的是一项多国家、多中心双盲随机对照研究,比较Locoid脂霜每日两次(前组)与Locoid脂霜和基质每日各一次外用(后组)治疗异位性皮炎的疗效。病员来源于1991年11月～1992年11月间丹麦等四个国家150例患者。每例患者用两管药,早上一管含赋形剂基质或Locoid脂霜,晚上一管均含Locoid脂霜,     

外用0.25％脱羟氟美松(Desoximetasone)霜治疗掌蹠脓疱病的临床经验

氟美松(Dexamethasone)的17α位缺-OH基即构成脱羟氟美松(Desoximetasone)简称(Des)。据研究Des的抗炎效果,口服是氟美松的5倍,皮下注射是4倍。作者报告外用0.25％Des霜(油包水)治疗掌蹠脓疱病20例,因2例掌蹠同时有皮损总计22例。手掌有皮损8例,足蹠有皮损14例。手掌皮损6例采用白天涂擦和夜间密闭敷贴,2例单用密闭敷贴。足蹠皮损6例采用白天涂擦和夜间密闭敷贴,7例单用密闭敷贴,1例仅白天涂擦。不并用其它疗法。大部分病例(15例)用药14日判断效果。治疗结果:22例中显效10例,有效7     

伊曲康唑与达克宁霜治疗念珠菌性龟头炎的疗效比较

我们于2001年12月～2003年12月应用伊曲康唑(商品名斯皮仁诺,西安杨森制药有限公司生产)治疗念珠菌性龟头炎80例,并与2％硝酸咪康唑霜(商品名达克宁霜,西安杨森制药有限公司生产)作疗效对比观察,结果报告如下。     

0.1%丁酸氢化可的松霜治疗126例湿疹皮炎疗效观察

我们自1999年10月起应用0.1％丁酸氢化可的松霜(来可得脂霜)治疗126例湿疹皮炎类皮肤病,获得了较满意的疗效,现将结果报道如下。     

羌月乳膏治疗面部脂溢性皮炎的临床观察

目的探讨中药制剂羌月乳膏治疗面部脂溢性皮炎的有效性和安全性。方法将入选的120例面部脂溢性皮炎患者随机分为观察组60例(予羌月乳膏)和对照组60例(予丁苯羟酸软膏),连续局部用药4周。并在治疗结束后随访2周。结果治疗组有效率与对照组差异无统计学意义,在复发率和安全性方面治疗组优于对照组,差异有统计学意义。结论中药制剂羌月乳膏是治疗脂溢性皮炎的安全有效的外用药,而且复发率低,可作为治疗面部脂溢性皮炎的一线用药。     

萘替芬酮康唑乳膏治疗面部脂溢性皮炎疗效观察

目的 探讨萘替芬酮康唑乳膏和复方乳酸乳膏混合外涂治疗面部脂溢性皮炎的临床疗效和安全性。方法 将65例面部脂溢性皮炎患者随机分成两组,治疗组33例,将适量萘替芬酮康唑乳膏和复方乳酸乳膏1:1放于洗净的手掌,混合调匀,再均匀涂于面部皮损处;对照组32例,将适量曲安奈德尿素乳膏和复方乳酸乳膏以1:1按上法均匀涂于面部皮损处。疗程均为4周,每2周复诊1次,观察疗效和不良反应。结果 治疗第2,4周后,两组症状总积分均较治疗前显著下降,差异有统计学意义(P<0.05);治疗组有效率分别为72.73%和78.13%,对照组分别为81.82%和87.50%,差异均无统计学意义(P均>0.05)。结论 外涂萘替芬酮康唑乳膏与外涂曲安奈德尿素乳膏治疗面部脂溢性皮炎疗效均满意且相当,但外涂萘替芬酮康唑乳膏更安全,无糖皮质激素乳膏外用的不良反应。     

盐酸特比萘芬乳膏治疗面部脂溢性皮炎的临床疗效观察

目的评价盐酸特比萘芬乳膏外用治疗面部脂溢性皮炎的疗效与安全性。方法 78例面部脂溢性皮炎患者随机分成两组,试验组39例,接受盐酸特比萘芬乳膏外用治疗,每日2次;对照组39例,接受复方益康唑乳膏治疗,每日2次。两组患者疗程均为4周,每2周复诊1次,复诊时观察和记录疗效和不良反应,治疗结束1个月后对两组患者进行随访。结果治疗2、4周后,两组患者症状总积分均较治疗前明显下降,差异有统计学意义(P0.01)。治疗2周后,试验组和对照组总有效率分别为71.8%和76.9%;治疗4周后,试验组和对照组总有效率分别为79.5%和84.6%,组间差异均无统计学意义(P0.05)。此外,治疗4周后两组患者马拉色菌菌量均比治疗前明显减少,且试验组可检出马拉色菌菌量明显少于对照组。1个月后随访结果表明,试验组复发率为7.7%,显著低于对照组的43.8%。试验组和对照组不良反应发生率分别为10.3%和30.8%。结论外用盐酸特比萘芬乳膏与外用复方益康唑乳膏治疗面部脂溢性皮炎疗效均令人满意,但外用盐酸特比萘芬乳膏的复发率更低,且无糖皮质激素乳膏外用所致的不良反应。     

Clinical efficacies of topical agents for the treatment of seborrheic dermatitis of the scalp: A comparative study

Previous studies have shown that topical steroid and shampoo containing zinc pyrithione provide clinical benefits for treatment of scalp seborrheic dermatitis. But the clinical efficacy of topical tacrolimus, a newly developed calcineurin inhibitor on seborrheic dermatitis, is not well investigated yet. We wanted to compare the clinical efficacy of topical tacrolimus with that of conventional treatment (zinc pyrithione shampoo and topical betamethasone) for treatment of seborrheic dermatitis of the scalp. Patients with seborrheic dermatitis of the scalp were randomly allocated to receive topical betamethasone, topical tacrolimus or zinc pyrithione shampoo. Some patients were instructed to continue the treatments for 8 weeks and the others to discontinue the treatments at week 4. We evaluated the efficacy using a clinical severity score, dandruff score and sebum secretion at baseline, week 4 and week 8. All treatment groups showed significant improvements in clinical assessment after 4 weeks. While the patients treated by zinc pyrithione improved continuously even after cessation of the treatment, the patients treated by betamethasone lotion or tacrolimus ointment were aggravated clinically. Topical tacrolimus was as effective as topical betamethasone, and showed more prolonged remission than topical betamethasone. To treat seborrheic dermatitis of the scalp, we think that the combination therapy of topical steroid or topical tacrolimus, and zinc pyrithione is recommended.     

曲安奈德益康唑乳膏治疗脂溢性皮炎78例临床观察

目的观察曲安奈德益康唑乳膏治疗微生物相关皮肤病脂溢性皮炎的临床疗效及安全性。方法治疗组78例脂益性皮炎患者，予早、晚各1次外用曲安奈德益康唑乳膏，并轻揉搓片刻，疗程4周。对照组80例予外搽皮炎平，用药方法及疗程同前。每周复诊时观察皮损情况。结果治疗组有效率89．3％，对照组为66．6％；治疗组出现不良反应3例，占3．8％，均予对症处理，与对照组（8例）比较差异有统计学意义（P〈0．05）。结论曲安奈德益康唑乳膏治疗脂溢性皮炎疗效确切，不良反应少。     

二丙酸倍他米松乳膏治疗慢性湿疹临床观察

目的价二丙酸倍他米松乳膏治疗慢性湿疹的近期临床疗效和安全性。方法采用随机、开放、平行对照的方法将120例慢性湿疹患者分为两组,治疗组和对照组分别外用0.05%二丙酸倍他米松乳膏和卤米松乳膏,2次/d,疗程2周,治疗结束后观察两组患者的治疗结果。结果治疗组有效率98.31%,对照组69.49%,治疗组有效率明显高于对照组,差异有统计学意义(P<0.01),两组均无严重不良事件发生。结论 0.05%二丙酸倍他米松乳膏治疗慢性湿疹临床疗效可靠,安全性高。     

Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1a-24 (R)-dihydroxycholecalciferol (tacalcitol) cream

A 71-year-old woman visited our clinic due to the presence of widespread scaly erythema on her face, scalp, and lower extremities. She was tentatively diagnosed as having seborrheic dermatitis but the symptoms were difficult to distinguish from psoriasis vulgaris. As a result, she was diagnosed as having sebopsoriasis. She was treated topically with an active vitamin D3 compound, 1a-24 (R)-dihydroxycholecalciferol D3 (tacalcitol) cream. She applied tacalcitol cream twice daily for 4 weeks, and her facial eruptions thus cleared up completely. No recurrence was observed for 2 months thereafter, even though the use of tacalcitol cream was stopped. To investigate whether or not tacalcitol cream is generally effective for the treatment of such seborrheic dermatitis-like eruptions, three more patients were treated with tacalcitol cream. All patients exhibited scaly erythematous macules on the face and/or scalp, and their eruptions improved rapidly with tacalcitol cream. Tacalcitol cream was thus found to be effective and useful for the treatment of both sebopsoriasis and even seborrheic dermatitis of the face and scalp.     

Nicolau Syndrome Following Etanercept Administration

Background: Treatment options for seborrheic dermatitis are numerous, including both topical and systemic agents (e.g. topical corticosteroids, oral antifungals, and psoralen plus UVA). However, long-term use of topical corticosteroids may lead to adverse effects. Pimecrolimus 1% cream is an effective and well tolerated treatment for seborrheic dermatitis. Objective: To explore the efficacy of pimecrolimus 1% cream for the treatment of seborrheic dermatitis lesions resistant to conventional treatments. Methods: Sixteen patients with resistant seborrheic dermatitis of the face applied pimecrolimus 1% cream twice daily for 2 weeks. The lesions were assessed clinically and the severity of the signs were assessed using a 4-point score. Additionally, the scores of all affected regions (paranasal, forehead, and eyebrows) were evaluated separately to assess whether different results would be obtained in different regions of the face. Also, patients completed self-assessments on a 100 mm Visual Analogue Scale (VAS) at each visit. Results: Statistically significant reductions in the scores of all parameters were observed at day 7 and day 14 of the study. There were no significant differences between the responses on the three regions of the face. No adverse effects were reported except for temporary pruritus immediately after the application of pimecrolimus 1% cream in one patient. Conclusion: Although the interpretation of efficacy was limited by the open-label, non-controlled study design and the small number of patients, this trial suggests that pimecrolimus 1% cream may be a successful treatment choice for patients with resistant seborrheic dermatitis of the face.     

Management of eczematous dermatitis with amcinonide or betamethasone valerate. A double-blind comparative study.

A new topical corticosteroid formulation, 0.1 percent amcinonide cream, was compared with 0.1 percent betamethasone valerate cream in a double-blind, parallel study of the management of eczematous dermatitis. Both treatment groups showed statistically significant improvement in most symptoms and in overall disease status after one and two weeks of treatment. The amcinonide group had greater improvement in individual symptoms and significantly greater overall improvement than did the betamethasone valerate group. Side effects were few and minor in both groups. The amcinonide cream was found to be both safe and effective for the management of eczematous dermatitis.     

Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study

BACKGROUND: Recently, two placebo-controlled studies have shown that topical metronidazole was effective in the treatment of seborrheic dermatitis. OBJECTIVE: To compare the efficacy and safety of metronidazole 0.75% gel with that of ketoconazole 2% cream in the treatment of facial seborrheic dermatitis. METHODS: A total of 60 consecutive patients with facial seborrheic dermatitis were included. Patients were randomized into two groups. One group used ketoconazole 2% cream with metronidazole gel as vehicle; the other group used metronidazole 0.75% gel with ketoconazole cream as vehicle for a 4-week treatment period. Main outcome measures were change in clinical severity scores, patients' and investigator's global evaluation of improvement and frequency of side-effects. RESULTS: All the assessments were made by an investigator who was unaware of which group the patients were allocated to. Mean percentage decrease in clinical severity scores from baseline to last available visit was 63.4% (95% CI 57.7-69) and 54.4% (95% CI 47.9-61) in the ketoconazole- and metronidazole-treated patients, respectively (P = 0.31). Eighty-two per cent of patients in the ketoconazole group vs. 79% of patients in the metronidazole group rated their global improvement as significant or moderate (P > 0.05). No statistically significant difference in the frequency of side-effects was detected between the two groups. The results of this study need to be confirmed in further studies involving large numbers of patients. CONCLUSION: Our data demonstrated that metronidazole 0.75% gel had a comparable efficacy and safety profile with that of ketoconazole 2% cream in the treatment of facial seborrheic dermatitis.